TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health SectorBusiness Wire • 08/23/21
TherapeuticsMD's (TXMD) CEO Rob Finizio on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/04/21
Will TherapeuticsMD (TXMD) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 07/28/21
TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDABusiness Wire • 05/25/21
The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 AwardBusiness Wire • 05/24/21
TherapeuticsMD, Inc. (TXMD) CEO Rob Finizio on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual MeetingBusiness Wire • 05/03/21
TherapeuticsMD (TXMD) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/28/21
TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in BelgiumBusiness Wire • 04/08/21
EU & UK Conclude Decentralised Procedure Approval for Bijuva® (Estradiol & Progesterone) Capsules for Hormone Replacement TherapyBusiness Wire • 03/03/21
TherapeuticsMD, Inc. (TXMD) CEO Robert Finizio on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/02/21